Clinical trial results:
A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer.

Summary

EudraCT number	2016-002222-37
Trial protocol	DK
Global end of trial date	08 February 2018

Results information

Result version number	v1 (current)
This version publication date	12 October 2019
First version publication date	12 October 2019

Trial information

Trial identification

Sponsor protocol code	1626

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Herlev Hospital
Sponsor organisation address	Herlev Ringvej 75, Herlev, Denmark, 2730
Public contact	Dorte Nielsen, Oncology dept. Herlev og Gentofte Hospital, +45 38682344, dorte.nielsen.01@regionh.dk
Scientific contact	Dorte Nielsen, Oncology dept. Herlev og Gentofte Hospital, +45 38682344, dorte.nielsen.01@regionh.dk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 February 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	08 February 2018
Global end of trial reached?	Yes
Global end of trial date	08 February 2018
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Overall survival between the two groups

Protection of trial subjects:

Eligibility criteria, no additional specific measures

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 September 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Denmark: 7
Worldwide total number of subjects	7
EEA total number of subjects	7

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	4
From 65 to 84 years	3
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Recruitment was open from september 2016 to october 2017, single center trial at Herlev University Hospital

Pre-assignment

Screening details:

not applicable

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Regorafenib

Arm description:

Experimental arm

Arm type	Experimental
Investigational medicinal product name	Regorafenib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

160 mg daily for 3 weeks in a 4-weeks cycle

Arm title	Standard

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	Irinotecan
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

180 mg/m2 every 2 weeks

Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

5 mg/kg every 2 weeks

Investigational medicinal product name	Panitumumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:
6 mg/kg every 2 weeks

Number of subjects in period 1	Regorafenib	Standard
Started	3	4
Completed	3	4

Baseline characteristics

Reporting groups	
Reporting group title	Regorafenib
Reporting group description:	
Experimental arm	
Reporting group title	Standard
Reporting group description: -	

Reporting group values	Regorafenib	Standard	Total
Number of subjects	3	4	7
Age categorical			
Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous			
Units: years			
median	67	59.5	
full range (min-max)	56 to 68	58 to 70	-
Gender categorical			
Units: Subjects			
Female	1	2	3
Male	2	2	4

End points

End points reporting groups

Reporting group title	Regorafenib
Reporting group description: Experimental arm	
Reporting group title	Standard
Reporting group description: -	

Primary: OS

End point title	OS[1]
End point description:	
End point type	Primary
End point timeframe: From time of randomisation to death or last FU	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses not performed due to low number of patient

End point values	Regorafenib	Standard		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	4		
Units: year				
median (full range (min-max))	5.6 (3.1 to 7.1)	7.1 (2.3 to 8.9)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events: Treatment start to 30 days after last treatment	
Assessment type	Systematic

Dictionary used	
Dictionary name	NCI-CTCAE
Dictionary version	4.0

Reporting groups	
Reporting group title	Regorafenib
Reporting group description: Experimental arm	
Reporting group title	Standard
Reporting group description: -	

Serious adverse events	Regorafenib	Standard	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 3 (33.33%)	1 / 4 (25.00%)	
number of deaths (all causes)	2	2	
number of deaths resulting from adverse events	0	0	
General disorders and administration site conditions			
Syncope			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Paresis OE dex			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Regorafenib	Standard	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	4 / 4 (100.00%)	
Investigations			
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	
occurrences (all)	0	1	
Thrombocytopenia			
subjects affected / exposed	0 / 3 (0.00%)	2 / 4 (50.00%)	
occurrences (all)	0	2	
Cardiac disorders			
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 3 (33.33%)	0 / 4 (0.00%)	
occurrences (all)	1	0	
Febrile neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 4 (25.00%)	
occurrences (all)	0	1	
Gastrointestinal disorders			
Diarrhea			
subjects affected / exposed	1 / 3 (33.33%)	3 / 4 (75.00%)	
occurrences (all)	1	3	
Nausea			
subjects affected / exposed	1 / 3 (33.33%)	3 / 4 (75.00%)	
occurrences (all)	1	3	
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	4 / 4 (100.00%)	
occurrences (all)	0	4	
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 3 (0.00%)	2 / 4 (50.00%)	
occurrences (all)	0	2	
Palmar-plantar erythrodysaesthesia syndrome			

subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 4 (0.00%) 0	
Metabolism and nutrition disorders Anorexia subjects affected / exposed occurrences (all)	 1 / 3 (33.33%) 1	 2 / 4 (50.00%) 2	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

recruitment goal not reached

Notes: